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ABSTRACT
Surgical site infection risk continues to increase due to lack of efficacy in current standard of care 
drugs. New methods to treat or prevent antibiotic-resistant bacterial infections are needed. 
Multivalent Adhesion Molecules (MAM) are bacterial adhesins required for virulence. We devel-
oped a bacterial adhesion inhibitor using recombinant MAM fragment bound to polymer scaffold, 
mimicking MAM7 display on the bacterial surface. Here, we test MAM7 inhibitor efficacy to 
prevent Gram-positive and Gram-negative infections. Using a rodent model of surgical infection, 
incision sites were infected with antibiotic-resistant bioluminescent strains of Staphylococcus 
aureus or Pseudomonas aeruginosa. Infections were treated with MAM7 inhibitor or control 
suspension. Bacterial abundance was quantified for nine days post infection. Inflammatory 
responses and histology were characterized using fixed tissue sections. MAM7 inhibitor treatment 
decreased burden of S. aureus and P. aeruginosa below detection threshold. Bacterial load of 
groups treated with control were significantly higher than MAM7 inhibitor-treated groups. 
Treatment with inhibitor reduced colonization of clinically-relevant pathogens in an in vivo 
model of surgical infection. Use of MAM7 inhibitor to block initial adhesion of bacteria to tissue 
in surgical incisions may reduce infection rates, presenting a strategy to mitigate overuse of 
antibiotics to prevent surgical site infections.
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Introduction
Surgical site infections (SSIs) have become the most 
common and costly of hospital-acquired infections. It 
is estimated that 20% of all hospital-acquired infections 
are related to surgical site infections, which directly 
increase hospital length of stay and risk of mortality. 
Of the in-hospital mortalities with an SSI at the time of 
death, 77% of cases are directly attributable to the 
surgical site infection [1,2]. Despite the guidelines cur-
rently in place to prevent or reduce the incidence of 
SSIs, they remain a persistent and costly challenge[3].
With the increase in antibiotic resistant bacteria and the 
narrowing pipeline for developing new effective antimicro-
bials, the challenges for treating infection are ever more 
difficult. ESKAPE pathogens (Enterococcus faecium, 
Staphylococcus aureus, Klebsiella pneumoniae, 
Acinetobacter baumannii, Pseudomonas aeruginosa and 
Enterobacter species) are frequently associated with hospital 
acquired infections [4–6] and are the predominant patho-
gens identified in combat casualties [6–8]. Due to drug 
efflux mechanisms and genetically acquired drug resis-
tance, antibiotic tolerance has increased in these species 
[9]. These characteristics have led to the rise of multidrug- 
resistant isolates that are observed in patients and trans-
ferred between patients through healthcare personnel or 
hospital equipment [6,10,11]. The intrinsic modes of bac-
terial defense allow for persistence in clinical settings, and, 
the current treatments that use more antibiotics, are asso-
ciated with increasing antimicrobial resistance[12]. Given 
the link between increased antibiotic use and the increases 
in antibiotic resistance, a large interdisciplinary task force 
highlighted the need for better stewardship of antimicrobial 
agents across surgical disciplines to decrease the expansion 
of antimicrobial resistance in surgical infections[12]. An 
urgent need is now recognized for new antimicrobial 
drugs. Bactericidal and bacteriolytic antimicrobials exert 
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strong selective pressure, leading to the rapid emergence of 
drug-resistance. Thus, antimicrobials that target virulence, 
rather than growth, are sought out as a potential alternative 
[13,14]. Such anti-virulence drugs are thought to exert no 
selective pressure on the emergence of antimicrobial resis-
tance[15]. There are several different strategies that have 
been explored for their potential to prevent or treat bacterial 
infections[16]. These have included compounds that target 
bacterial attachment/adherence [17,18], biofilm formation 
[19], secretion systems [20,21], or bacterial toxins [22–25]. 
Often these compounds target a specific bacterial strain or 
species, and do not have broad-spectrum efficacy[16].
Recently, we identified Multivalent Adhesion Molecules 
(MAMs) as a widespread family of bacterial adhesins that 
facilitate bacterial colonization of host tissues[26]. 
Multivalent adhesion molecule 7 (MAM7) is a bacterial 
outer membrane protein that facilitates host cell adhesion 
by Gram-negative bacteria[26]. We engineered a bacterial 
adhesion inhibitor that consists of a recombinant fragment 
of MAM7 chemically coupled to a micron-sized, spherical 
polystyrene scaffold [27] to mimic its endogenous presen-
tation on the bacterial surface. This inhibitor attaches to 
host surface receptors fibronectin and phosphatidate, 
which are commonly used by bacteria to colonize tissues, 
inhibiting bacterial attachment by competitive exclusion 
[28]. We evaluated the MAM7-based adhesion inhibitor 
specifically for its efficacy against multidrug-resistant bac-
teria isolated from wounded military personnel, including 
A. baumannii, K. pneumoniae, P. aeruginosa and ESBL- 
producing E. coli, and found it to be effective against 21 out 
of 25 (84%) of tested isolates in vitro[29]. MAM7 inhibitor 
beads have been used in vitro to prevent Gram-negative 
pathogens and methicillin resistant Staphylococcus aureus 
from binding to host cells, thereby inhibiting subsequent 
infection and cytotoxicity in cultured cell models [29–32]. 
To our knowledge, MAM7 inhibitor beads are the first 
reported virulence-targeting compound with a broad spec-
trum activity against both Gram-positive and Gram- 
negative bacteria. In vitro and in vivo studies showed that 
MAM7 inhibitor beads do not interfere with wound heal-
ing [30,33]. Recently, we tested the efficacy of MAM7 
inhibitor beads using an in vivo rodent model of multi-
drug-resistant Pseudomonas aeruginosa burn wound infec-
tion[33]. The MAM7-based adhesion inhibitor restricted 
both bacterial load and spatial spread of the infection in 
burn wounds[33].
The aim of this current study was to test if MAM7 
inhibitor beads could prevent infections in a clinically 
relevant model of surgical site infection. In this model, 
we used two species of drug-resistant bacteria that are 
frequently associated with surgical site infections, 
Staphylococcus aureus and Pseudomonas aeruginosa.
Materials and methods
Bacterial strains and growth conditions
Pseudomonas aeruginosa strain Xen5 (PerkinElmer), 
a bioluminescent derivative of a blood isolate from 
a septic patient (strain ATCC 19660), was used 
throughout the experiments. The strain is resistant to 
carbenicillin, chloramphenicol, tetracycline and tri-
methoprim by Kirby-Bauer Disk Diffusion Test. 
Staphylococcus aureus strain Xen36 (PerkinElmer), 
a bioluminescent derivative of a clinical isolate from 
a bacteremic patient (ATCC 49525). The strain is resis-
tant to kanamycin and penicillin by Kirby-Bauer Disk 
Diffusion Test. P. aeruginosa was grown in Luria- 
Bertani broth (LB) and S. aureus was grown in 
Trypticase Soy Broth (TSB) at 37°C under constant 
aeration. Inoculum bacteria was grown in log-phase to 
an optical density of 1.0. Bacteria suspended in LB or 
TSB media was introduced directly into the wound via 
pipette.
Synthesis of inhibitor and control beads
MAM7 (VP1611)ΔN44 was expressed with an N-terminal 
GST-tag, and purified as previously described[26]. Purified 
GST-MAM7ΔN44 or GST alone were chemically coupled 
to polystyrene microbeads, as previously described [27], to 
produce GST-MAM7 beads (inhibitor) and GST control 
beads, respectively.
Animal protocols, incision infection model
All animal protocols were reviewed and approved by 
the University of Texas Southwestern Medical Center 
Institutional Animal Care and Use Committee and 
followed the ARRIVE guidelines for animal research 
[34]. Adult male Sprague-Dawley rats (276–300 g) 
were obtained from Envigo Laboratories (Houston, 
TX). Animals were acclimated in house for seven days 
after arrival at UTSW. During acclimation rats had 
access to ad libitum commercial rat chow and water. 
Rats were housed under a 12 hour light/dark cycle. 
After acclimation, rats were individually housed for 
the remainder of the experiment. The surgical infection 
model described by Rupp et al [35]. and Kuklin et al 
[36]. were used with the following modifications. Rats 
were deeply anesthetized with isoflurane. While under 
anesthesia, the surgical area was shaved. With a scalpel, 
a 4 to 5 cm incision was constructed parallel to the 
vertebral column with a sterile scalpel. The incision was 
approximately 1 cm in depth into the paraspinous 
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muscle. 7.5⋅107 CFU of P. aeruginosa Xen5 or 1⋅107 
CFU of S. aureus Xen36 were directly applied into the 
incisional wound, followed by application of suspen-
sions containing 3⋅108 GST-MAM7 beads or GST con-
trol beads. The 107 CFU dose was previously tested in 
this model producing a consistently reproducible infec-
tion (unpublished data). A total of 10 individual ani-
mals were used for each condition (i.e. n = 10 
P. aeruginosa + MAM beads; n = 10 P. aeruginosa + 
Control beads; n = 10 S. aureus + MAM beads; 
n = 10 S. aureus + Control beads). Group size for 
animals inoculated with only bacteria was six. Group 
size was determined based upon previously published 
data[33]. Subsequently the incision was sutured closed 
immediately with 3–0 Prolene suture. Sutures remained 
in the animal for the duration of the experiment. 
Animals were imaged daily, using an IVIS Spectrum 
In vivo Imaging System (PerkinElmer). Measurements 
of photon flux emitted from bioluminescent bacteria in 
the wound were used as a proxy for bacterial abun-
dance/burden. Photon flux has been used previously to 
determine bacterial abundance, and correlates with col-
ony forming unit data [37,38]. Animals were sacrificed 
if they became moribund, or at the end of the experi-
ment (9 days after surgery). At the end of the experi-
ment, animals were euthanized via exsanguination by 
cardiac puncture while under isoflurane anesthesia. 
Blood and tissue were collected from each animal 
immediately postmortem. All procedures (surgical, 
imaging, and euthanasia) were conducted in the morn-
ing during the light cycle. Daily mean bacterial burdens 
± standard errors of the mean (sem) were calculated for 
each experimental group. Statistical significance in bac-
terial burdens between groups compared to untreated, 
infected animals was then determined by analysis of 
variance (ANOVA) and Dunnett’s multiple compari-
sons test, using GraphPad Prism 7. Adjusted P-values 
of P˂0.0001 (****) indicate extremely significant, 
P˂0.05 (*) significant, and P ≥ 0.05 (ns) not significant 
results, respectively.
Tissue preparation and histology
A portion of the dorsal skin was fixed overnight in 10% 
neutral buffered formalin (NBF) and paraffin embedded. 
Tissue sections (5 μm) were deparaffinized and rehy-
drated using graded alcohol concentrations followed by 
H&E staining or immunofluorescence (IF) staining. For 
IF staining, formalin-fixed and paraffin embedded skin 
tissue sections were deparaffinized in xylene and rehy-
drated using graded alcohol concentrations. Samples 
were then boiled in 10 mM citric acid for 20 min to 
retrieve epitopes. Sections were permeabilized with 1% 
Triton X-100 and blocked with 2% BSA in PBS-T. 
Primary antibody incubation (anti-myeloperoxidase, 
1:100, Abcam ab9535) was carried out overnight at 4°C 
in PBS-T + 1% BSA, and secondary antibody incubation 
(anti-rabbit Alexa-488, 1:500, ThermoFisher A-11034) 
was performed over 1 h at room temperature. Sections 
were finally stained for DNA using Hoechst 
(ThermoFisher, 33342) and mounted (Prolong gold anti-
fade, ThermoFisher P36930). Fluorescence images were 
acquired on a Zeiss LSM710 confocal microscope and 
processed using Image J and CorelDraw X5. H&E images 
were examined for gross morphology and IF images were 
examined for gross presence/abundance of neutrophils.
Wound healing RT-qPCR assays
In an effort to examine for potential inhibitory effects 
that MAM7 may have on wound healing, a group of 
non-infected animals received sham treatment (N = 3), 
control beads (N = 3), or MAM7 inhibitor (N = 3) within 
the surgical incision. Animals that were sham treated 
received a surgical incision and then were sutured closed. 
Additionally, we measured expression levels of matrix 
metalloproteinases (matrix metalloproteinase 2 (MMP- 
2), matrix metalloproteinase 9 (MMP-9) and tissue inhi-
bitor of metallopeptidase (TIMP-1)) to determine the 
effects on wound healing by real-time quantitative PCR 
(RT-qPCR). RNA was extracted from a portion of dorsal 
skin at the incision site using the RNAeasy Universal kit 
(Qiagen). cDNA conversion was conducted using the 
QuantiTect reverse transcription kit according to the 
manufacturer’s protocol (Qiagen). Quantitative assess-
ment of each gene transcript was conducted in triplicate 
for each individual animal with the TaqMan Fast 
Advanced Master Mix and TaqMan probes specific for 
each gene according to the manufacturer’s protocol 
(PerkinElmer). Levels of gene expression were calculated 
using the ΔΔCt method normalized to GAPDH 
(Glyceraldehyde 3-phosphate dehydrogenase) expres-
sion levels. The mean normalized ΔΔCt values for each 
group were compared using paired t-tests in GraphPad 
Prism 7. P-values<0.05 were interpreted as statistically 
significant.
Bacterial attachment to microbeads
GST was chemically coupled to polymer beads as 
described above. To allow visualization of beads by fluor-
escence microscopy, beads with an identical surface 
chemistry as those above, but with a fluorescent blue 
core were used (Sigma, #L0280). P. aeruginosa Xen5 and 
S. aureus Xen36 were grown at 37°C for 16 h as described 
above. Bacteria were washed with DMEM, and added to 
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GST coupled beads in DMEM to give final concentrations 
of 5.6 ⋅108 CFU/ml of P. aeruginosa + 1.2 ⋅109 beads/ml, 
and 4⋅107 CFU/ml of S. aureus + 1.2 ⋅109 beads/ml, 
respectively, reflecting the initial ratios of bacterial inocula 
and beads used in the laceration model. Suspensions of 
bacteria and beads were incubated at 37°C under static 
conditions. At 24 and 48 h, samples were removed and 
bacteria stained using the membrane dye FM 4–64FX 
according to the manufacturer’s protocol. Samples were 
mounted on 1.5% agarose pads and imaged using an 
Olympus IX83 inverted microscope fitted with 
a FV3000 laser scanning confocal system and a Plan 
Super Apochromat 100 × 1.40NA oil objective. Images 
were processed using Olympus CellSens Dimension soft-
ware and deconvolution package (5 iterations). For each 
field, z-stacks were collected (0.2 µm increments) and 
representative maximum intensity projections are shown.
Results
We explored the efficacy of MAM7 bacterial adhesion 
inhibitor against bacterial infections of Pseudomonas 
aeruginosa and Staphylococcus aureus in an in vivo 
model of surgical site infection. After creation of the 
surgical incision, animals were inoculated with 7.5⋅107 
CFU of Pseudomonas aeruginosa or 1⋅107 CFU of 
Staphylococcus aureus. After inoculation, a suspension 
of adhesion inhibitor (3⋅108 GST-MAM7-coupled 
beads) or control beads (3⋅108 GST-coupled beads 
were applied directly into the surgical site, and inci-
sions were sutured closed (Day 0, Figure 1(a)). Daily 
quantification of bacterial abundance was carried out 
by IVIS imaging (Figure 1(a)), and photon flux data 
was converted into bacterial burden by measuring the 
flux of known CFUs for each bacterial strain (see 
methods section). The P. aeruginosa burden in the 
MAM7 inhibitor treated group consistently decreased 
over the experimental time course (Figure 1(c)), result-
ing in a 10-fold reduction in the GST-MAM7 bead 
treated group relative to the control group within the 
first 24 hours (Figure 1(d)). Bacterial burden in the 
MAM7 inhibitor treatment group further declined 
between days 1–9 post surgery, and was as low as the 
detection limit at 5–9 days. In the presence of control 
beads, the inoculum of P. aeruginosa introduced into 
the incision doubled within the initial 24 hours follow-
ing surgery and steadily increased thereafter, reaching 
a maximum at day 5 post infection (Figure 1(b,d)). 
Between day 5–9, the experimental endpoint, the bac-
terial burden decreased back to the original inoculum, 
but was not resolved to the extent seen in animals 
treated with MAM7 inhibitor beads (Figure 1(b-d)). 
Bacterial burden in animals inoculated with bacteria, 
but left untreated (no MAM7 adhesion inhibitor or 
control beads) showed a similar profile to those treated 
with GST control beads (Figure 1(d)).
Our previous in vitro studies showed that GST-MAM7 
beads could block host cell colonization by Gram-positive 
bacteria that share common surface receptors with 
MAM7, in particular by S. aureus, which also attach to 
fibronectin to colonize host tissues[29]. These prior stu-
dies suggested that GST-MAM7 beads may potentially be 
able to inhibit S. aureus tissue colonization in vivo. Here, 
we tested this hypothesis by determining the in vivo effi-
cacy of GST-MAM7 beads against S. aureus infection in 
the surgical site infection model. Incisions infected with 
S. aureus and treated with GST control beads did not fully 
heal, and in many cases animals developed bacterial 
abscesses under the skin (Figure 2(a)). In contrast, 
infected incisions treated with GST-MAM7 beads had 
visually resolved the infection by 9 days post-surgery, 
showed minimal bacterial infiltration, and the wound 
was fully healed. IVIS imaging data was in line with visual 
inspection of surgical sites: In incisions treated with GST 
control beads, S. aureus rapidly expanded (approx. 5-fold 
within the initial 24 hours post inoculation), and the 
bacterial burden peaked at 5 days post infection (Figure 
2(b,d)), similar to what was observed with P. aeruginosa 
(Figure 1). In contrast, bacterial load remained restricted 
in GST-MAM7 treated incisions (peak load approx. 
3-fold lower compared to GST control group, Figure 2 
(c,d)), and steadily decreased thereafter, dropping below 
detectable burdens at 4 days post-surgery (Figure 2(d)). 
Bacterial abundance in animals inoculated with S. aureus 
but left untreated (no MAM7 adhesion inhibitor or con-
trol beads) showed a similar profile as in those treated 
with GST control beads (Figure 2(d)).
Fixed sections taken from surgical incisions were 
subjected to H&E staining (Figure 3) and examined 
histologically. Uninfected incisions treated with GST 
control beads (Figure 3(b)) or GST-MAM7 inhibitor 
beads (Figure 3(c)) did not show any signs of disrupted 
wound healing, and were histologically similar to the 
sham treatment incisions (Figure 3(a)). Within the 
infected groups, incisions infected with P. aeruginosa 
and S. aureus and treated with control beads (Figure 3 
(d,f)) showed extensive tissue damage and immune cell 
infiltration, while incisions infected with either 
P. aeruginosa or S. aureus and treated with MAM7 
inhibitor beads (Figure 3(e,g)) histologically resembled 
the sham treatment incisions at 9 days post-surgery 
(Figure 3(a)). The epidermis in groups treated with 
MAM7 inhibitor beads was fully healed at 9 days post- 
surgery. Both the P. aeruginosa and S. aureus infections 
treated with GST control beads failed to fully restore 
the epidermis at 9 days post-surgery. Uninfected 
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groups treated with MAM7 inhibitor beads or GST 
control beads were able to restore the integrity of the 
epidermis at 9 days post-surgery (Figure 3(b,c)).
In an effort to quantify the effects of GST-MAM7 or 
GST control beads on wound healing, expression levels 
of several matrix metalloproteinases were measured at 
the wound site 9 days post-surgery. The expression 
levels of matrix metalloproteinases at the wound site 
were measured by quantitative PCR in the uninfected 
incision groups only. Levels of MMP-2 (2.64 ± 0.16: 
2.74 ± 0.16: 3.1 ± 0.6, p > 0.57), MMP-9 (3.81 ± 0.63: 
5.18 ± 1.1: 4.86 ± 0.76, p > 0.38), and TIMP-1 
(3.05 ± 0.73: 3.4 ± 0.72: 2.42 ± 0.39, p > 0.26) were 
not significantly different between sham treated inci-
sions, and incisions treated with GST-MAM7 beads, or 
GST control beads.
Infiltration of neutrophils was examined by myelo-
peroxidase staining (Figure 4). An absence of neutro-
phils was noted in the sham (Figure 4(a)) and in the 
uninfected lacerations treated with GST control beads 
(Figure 4(b)) or GST-MAM7 inhibitor beads (Figure 4 
(c)). The presence of neutrophils was observed in both 
Figure 1. Treatment of surgical laceration wounds with a MAM7 inhibitor decreases Pseudomonas aeruginosa bacterial burden and 
spatially constrains the spread of infection. (a) Timeline of surgery, infection, inhibitor dosing, and imaging regimen. On day 0, 
animals were infected with 7.5?107 CFU of P. aeruginosa, and treated with 3?108 GST-MAM7 beads (inhibitor) or GST control beads, 
or the infection left untreated (no beads). Representative daily bioluminescence images of infected surgical incisions treated with 
GST control beads (b) or GST-MAM7 inhibitor beads (c). (d) Quantification of P. aeruginosa bacterial burden (as colony forming units, 
CFU) in animals treated with GST-MAM7 inhibitor beads (red), GST control beads (blue), and infected but otherwise untreated 
animals (orange), based on IVIS biophotonic imaging. Dotted black line represents detection limit (9?105 CFU). Values are mean 
burdens ± SEM (n = 10 for MAM bead- and control bead treatment groups; n = 6 for untreated infection group). Statistical 
significance between burdens in untreated infections relative to MAM inhibitor bead treatment and control bead treatment was 
determined by one-way ANOVA and a Dunnett’s multiple comparisons test. Adjusted P-Values are indicated in the graph.
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P. aeruginosa and S. aureus infected lacerations treated 
with GST control beads (Figure 4(d,f)). Additionally, 
neutrophils were detected at the site of infection in 
lacerations infected with P. aeruginosa and treated 
with GST-MAM7 beads (Figure 4(e)). Within 
S. aureus infected incisions treated with GST-MAM7 
beads, neutrophils were notably absent (Figure 4(g)).
Attachment of bacteria to GST-functionalized 
microbeads was examined following co-incubation of 
beads and S. aureus or P. aeruginosa in DMEM 
(Figure 5). An absence of bacterial attachment to the 
microbeads was noted at both 24 (Figure 5(a,c)) and 
48 hours of incubation (Figure 5(b,d)), for both 
S. aureus and P. aeruginosa.
Figure 2. Treatment of surgical laceration wounds with a MAM7 inhibitor decreases Staphylococcus aureus bacterial burden and 
spatially constrains the spread of infection. On day 0, animals were infected with 107 CFU of S. aureus, and treated with 3?108 GST- 
MAM7 beads (inhibitor) or GST control beads, or the infection left untreated (no beads). (a) Example of an abscess formed in an 
infected laceration treated with control beads. Representative daily bioluminescence images of infected surgical incisions treated 
with GST control beads (b) or GST-MAM7 inhibitor beads (c). (d) Quantification of S. aureus bacterial burden (as colony forming units, 
CFU) in animals treated with GST-MAM7 inhibitor beads (red), GST control beads (blue), and infected but otherwise untreated 
animals (orange), based on IVIS biophotonic imaging. Dotted black line represents detection limit (9?105 CFU). Values are mean 
burdens ± SEM (n = 10 for MAM bead- and control bead treatment groups; n = 6 for untreated infection group). Statistical 
significance between burdens in untreated infections relative to MAM inhibitor bead treatment and control bead treatment was 
determined by one-way ANOVA and a Dunnett’s multiple comparisons test. Adjusted P-Values are indicated in the graph.
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Discussion
Collectively our data demonstrates the effectiveness of 
a virulence targeting antimicrobial compound with 
broad specificity in an in vivo model of surgical infection. 
Surgical infections remain a persistent problem and are 
the major complication following surgical intervention. 
Previously we reported that microbeads functionalized 
with a recombinant fragment of the adhesin MAM7 
(MAM7-beads) could prevent Pseudomonas aeruginosa 
colonization and spread of infection in a burn wound 
model[33]. Although Pseudomonas has a high prevalence 
in burn wound infections [7,39], surgical infections are 
caused by a broader array of pathogens. This includes 
both Gram-negative and Gram-positive organisms, like 
Staphylococcus aureus. Although previous in vitro tests 
have demonstrated the efficacy of a MAM7 based inhibi-
tor against both Gram-negative and Gram-positive 
pathogens, it had not been tested in an in vivo model of 
infection against Gram-positive pathogens.
Here, we tested the ability of a MAM7 inhibitor 
against isolates of both a Gram-negative and a Gram- 
positive organism that exhibited broad resistance to 
antibiotics. The typical clinical threshold for deter-
mining a clinically significant infection is >105 colony 
forming units [40,41]. In an effort to exceed this 
threshold and mimic a high risk of surgical site infec-
tion, we used a dose of ≥107 CFU of each bacterial 
species to infect the surgical site. The 107 CFU dose 
was previously tested in this model producing 
a consistently reproducible infection (unpublished 
data). Subsequent to the incision, the infection was 
treated with an excess of MAM7 inhibitor or control 
beads and was then sutured closed. At 24 hours after 
surgery, there was a noticeable and statistically signif-
icant difference in bacterial abundance between the 
MAM7 and control bead treated groups for both the 
S. aureus and P. aeruginosa infections. Based upon 
previous in vitro data, the MAM7 inhibitor prevents 
the bacterial species from attaching and allows for 
normal clearance by the hosts immune system. This 
treatment allowed for the immune system to reduce 
the abundance of bacteria in the MAM7 treated group 
as shown by the reduction of daily bioluminescence 
measurements.
Alternatively, the control bead groups treated ani-
mals demonstrated daily increases of bacterial abun-
dance for five days post infection. Similar amounts of 
bacterial growth were noted for both the Gram-positive 
Figure 3. Histology of fixed skin sections from surgical incision model. Skin sections from tissues at 9 days post incision were 
subjected to hematoxylin and eosin staining. Dorsal skin sections are oriented with the epidermis at the top, and arrows denote the 
incisional site. Sections of uninfected incisions that were sham treated (a), treated with GST control beads (b), or GST-MAM7 inhibitor 
beads (c), or sections from incisions that were infected with 7.5 × 107 CFU of Pseudomonas aeruginosa and treated with GST control 
beads (d) or GST-MAM7 inhibitor beads (e), or infected with 107 CFU of Staphylococcus aureus and treated with GST control beads (f) 
or GST-MAM7 inhibitor beads (g) are shown.
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Figure 4. Neutrophil infiltration of surgical incisions. Immunofluorescence images of dorsal skin sections at 9 days post incision. 
Sections were stained with anti-myeloperoxidase (mpo) and anti-rabbit Alexa-488 to visualize neutrophils (green), and with Hoechst 
33342 to visualize DNA (blue). Scale bars, 200 μm; Arrows mark examples of neutrophil clusters. Imaged incisions were either 
uninfected and sham treated (a), treated with GST control beads (b), or GST-MAM7 inhibitor beads (c), or infected with of 
Pseudomonas aeruginosa and treated with GST control beads (d), or GST-MAM7 inhibitor beads (e), or infected Staphylococcus 
aureus and treated with GST control beads (f) or GST-MAM7 inhibitor beads (g).
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and Gram-negative species tested in this model. By the 
end of the experiment many of the bioluminescent 
values for individual animals in the MAM7 inhibitor 
treatment groups were indistinguishable from the back-
ground levels (levels measured on uninfected skin were 
1⋅106 photons/sec or 9⋅105 CFU on average). With this 
the level of bacteria in these individuals has completely 
resolved or was below the threshold for a clinically 
significant infection. Bacterial burdens in the control 
group persisted through the end of the experiment, 
where many of the animals had a notable abscess or 
purulent drainage at the wound site (Figure 2(a)). 
Foreign bodies following surgery are often colonized 
by bacteria and can lead to increased levels of infection 
[42]. However, both S. aureus and P.aeruginosa did not 
attach to the nanobeads (Figure 5) and bacterial bur-
dens in infections without nanobeads were similar to 
infections with the control beads. This suggests that the 
decreased bacterial colonization in the MAM7 inhibitor 
treatment group is linked to inhibition of bacterial 
attachment to cells, and not the presence of a foreign 
substrate (i.e. control nanobeads).
Elevated levels of MMP2 and MMP-9 have been asso-
ciated with wounds that have poor healing outcomes 
[43,44] and have been identified as potentially modifiable 
factors to accelerate wound healing [45,46]. Expression 
levels of MMP-2 and MMP-9 were not significantly differ-
ent between MAM7 inhibitor-, control bead-, and sham 
treated incisions. Our data is consistent with previous 
in vitro [30] and in vivo [33] studies where MAM7 inhi-
bitor did not alter wound healing. In addition to the 
reduction in bacterial abundance, histological examination 
demonstrated that treatment with MAM7 inhibitor or 
control beads did not affect wound closure compared to 
the sham incision. This is similar to what was demon-
strated in the burn wound models with infections treated 
with MAM7[33]. In both the P. aeruginosa and S. aureus 
groups that were treated with control beads the incisional 
wounds failed to completely heal. Whereas those treated 
with MAM7 inhibitor beads the incision were fully healed 
at 9 days post injury. Given the abundance of bacteria in 
the control bead groups, it is likely that the persistent 
infection was the cause of the wounds inability to heal. 
Increased levels of bacterial burden are known to inhibit 
wound healing [47,48]. The MAM7 inhibitor treatment 
was able to sufficiently reduce the bacterial burden in the 
wound to allow the wound to heal within nine days of 
surgery.
Neutrophils are an important component of the 
immune system for host defense and migration toward 
sites of injury and inflammation. In the examination 
for the presence of neutrophils at the surgical incision, 
at nine days post injury neutrophils were notably 
absent in the uninfected treatment groups (Figure 4). 
Both the MAM7 inhibitor and the GST bead control 
groups were similar to the uninfected incisions that 
received a sham treatment. Fundamentally, the lack of 
neutrophils in these groups represent an absence of 
acute inflammation. In the animals that received 
a bacterial infection, the number of neutrophils were 
minimal in the MAM7 groups compared to the GST 
treatment. Neutrophils were present in the GST treated 
Figure 5. Bacteria do not adhere to functionalized microbeads used to treat infected lacerations. P. aeruginosa (a, b) or S. aureus (c, 
d) were incubated with GST control beads for 24 h (a, c) or 48 h (b, d) and imaged. Representative maximum intensity projections of 
fluorescence confocal z-stack images are shown. Microbeads (blue); Bacteria (FM 4–64FX membrane stain, red); Aii-Dii represent 
magnified sections as denoted by white squares in Ai-Di. Scale bars, 10 µm.
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groups at the site of infection, which is indicative of 
neutrophil recruitment to an active bacterial infection. 
The minimal number of neutrophils noted in the 
infected and MAM7 inhibitor treated groups is concor-
dant with the bioluminescent imaging data, demon-
strating the significant reduction in bacterial levels for 
the MAM7 inhibitor treated groups. The differences 
noted between the abundance of neutrophils in the 
infected and GST control treated groups and the 
MAM7 inhibitor treated groups is also supportive of 
the hypothesis that blocking the initial attachment of 
bacteria allows for the host to more quickly remove the 
bacteria and resolve the infection.
Synthetic materials, including polymers, can be colo-
nized by bacteria and are often implicated in device- 
associated infections. We tested whether functionalized 
microbeads would be prone to bacterial colonization, 
imaging beads and bacteria used in the surgical site 
infection model following co-incubation. No bacterial 
adhesion to the bead surface was observed following up 
to 48 hours of co-incubation (Figure 5). Additionally, 
infections treated with GST control beads did not result 
in a higher bacterial burden relative to untreated infec-
tions where no beads were introduced into the incision 
(Figures 1(d) and 2(d)).
Taken together, the current study demonstrates that 
the use of GST-MAM7 beads as a bacterial adhesion 
inhibitor effectively reduces colonization by clinically 
relevant bacterial pathogens in an in vivo model of surgi-
cal site infection. In contrast to a previous study, where 
the MAM7-based inhibitor showed efficacy against 
P. aeruginosa in a burn wound infection model, and was 
administered daily, the present study is based on admin-
istration of a single dose of the inhibitor prior to wound 
suture. Additionally, the present study shows, for the first 
time, that the MAM7-based adhesion inhibitor has broad- 
spectrum efficacy, decreasing bacterial loads in both 
a Gram-negative and a Gram-positive infection to or 
below the detection limit. In conclusion, use of an inhi-
bitor that blocks the initial adhesion of bacteria to tissues 
is a promising approach to preventing SSIs and may be 
able to reduce bacterial infection rates and, thus, support 
antibiotic sparing strategies in an era of increasing chal-
lenges due to antibiotic resistance.
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